Literature DB >> 21487925

Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.

Avaniyapuram Kannan Murugan1, Jianli Dong, Jingwu Xie, Mingzhao Xing.   

Abstract

Frequent mutations in the GNAQ, MMP8, Akt3, EGFR, and PIK3R1 genes have been reported in human cancers but mostly have not been well examined in thyroid cancer. Selected exons of GNAQ, MMP8, AKT3, EGFR, and PIK3R1 genes were sequenced in various thyroid cancers. We found a G2203A EGFR mutation, resulting in a G735S amino acid change, in one of 21 (5%) papillary thyroid cancer samples. We did not find any mutation in the MMP8 gene, but observed a frequent SNP A259G (K87E) genotype switch in various types of thyroid cancer samples. We did not find any mutation in the GNAQ, AKT3, and PIK3R1 genes in various types of thyroid cancer. No mutation in these genes was found in 12 cell lines derived from various types of thyroid cancer. Therefore, unlike in other cancers, mutations in these genes are uncommon in thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487925      PMCID: PMC3133631          DOI: 10.1007/s12022-011-9155-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  22 in total

1.  Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.

Authors:  C Q Cai; Y Peng; M T Buckley; J Wei; F Chen; L Liebes; W L Gerald; M R Pincus; I Osman; P Lee
Journal:  Oncogene       Date:  2008-01-14       Impact factor: 9.867

2.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

Authors:  Constantine S Mitsiades; Vassiliki Kotoula; Vassiliki Poulaki; Elias Sozopoulos; Joseph Negri; Elpida Charalambous; Galinos Fanourakis; Gerassimos Voutsinas; Sophia Tseleni-Balafouta; Nicholas Mitsiades
Journal:  J Clin Endocrinol Metab       Date:  2006-07-05       Impact factor: 5.958

4.  Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Authors:  Yoshiaki Nagai; Hitoshi Miyazawa; Tomoaki Tanaka; Kiyoshi Udagawa; Motoyasu Kato; Shunichiro Fukuyama; Akemi Yokote; Kunihiko Kobayashi; Minoru Kanazawa; Koichi Hagiwara
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

5.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

Authors:  Zhi Liu; Peng Hou; Meiju Ji; Haixia Guan; Kimberly Studeman; Kirk Jensen; Vasily Vasko; Adel K El-Naggar; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

6.  Thyroid cancer incidence and socioeconomic indicators of health care access.

Authors:  Brian L Sprague; Shaneda Warren Andersen; Amy Trentham-Dietz
Journal:  Cancer Causes Control       Date:  2008-02-01       Impact factor: 2.506

7.  Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.

Authors:  Lavanya H Palavalli; Todd D Prickett; John R Wunderlich; Xiaomu Wei; Allison S Burrell; Patricia Porter-Gill; Sean Davis; Chenwei Wang; Julia C Cronin; Neena S Agrawal; Jimmy C Lin; Wendy Westbroek; Shelley Hoogstraten-Miller; Alfredo A Molinolo; Patricia Fetsch; Armando C Filie; Michael P O'Connell; Carolyn E Banister; Jason D Howard; Phillip Buckhaults; Ashani T Weeraratna; Lawrence C Brody; Steven A Rosenberg; Yardena Samuels
Journal:  Nat Genet       Date:  2009-03-29       Impact factor: 38.330

8.  Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma.

Authors:  Katsuhiro Masago; Ryo Asato; Shiro Fujita; Shigeru Hirano; Yoshihiro Tamura; Tomoko Kanda; Tadashi Mio; Nobuyuki Katakami; Michiaki Mishima; Juichi Ito
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

9.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Authors:  Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

10.  A novel AKT3 mutation in melanoma tumours and cell lines.

Authors:  M A Davies; K Stemke-Hale; C Tellez; T L Calderone; W Deng; V G Prieto; A J F Lazar; J E Gershenwald; G B Mills
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  17 in total

Review 1.  Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.

Authors:  Joshua J Gruber; A Dimitrios Colevas
Journal:  Oncologist       Date:  2015-01-23

Review 2.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

3.  Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Authors:  Federica Catalanotti; David B Solit; Melissa P Pulitzer; Michael F Berger; Sasinya N Scott; Tunc Iyriboz; Mario E Lacouture; Katherine S Panageas; Jedd D Wolchok; Richard D Carvajal; Gary K Schwartz; Neal Rosen; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

Review 4.  Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Authors:  Sujata Narayanan; A Dimitrios Colevas
Journal:  Curr Treat Options Oncol       Date:  2016-06

5.  Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

Authors:  J J Wheler; G S Falchook; A M Tsimberidou; D S Hong; A Naing; S A Piha-Paul; S S Chen; S Fu; B Stephen; J Y Fok; F Janku; R Kurzrock
Journal:  Ann Oncol       Date:  2012-11-08       Impact factor: 32.976

6.  Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data.

Authors:  Yumin Wang; Tingting Qin; Wangqiang Hu; Binghua Chen; Meijie Dai; Gang Xu
Journal:  Genes (Basel)       Date:  2018-01-11       Impact factor: 4.096

Review 7.  Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer.

Authors:  Hyon-Seung Yi; Joon Young Chang; Koon Soon Kim; Minho Shong
Journal:  Korean J Intern Med       Date:  2017-08-22       Impact factor: 2.884

8.  Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.

Authors:  Fatemeh Khatami; Bagher Larijani; Ramin Heshmat; Abbasali Keshtkar; Mahsa Mohammadamoli; Ladan Teimoori-Toolabi; Shirzad Nasiri; Seyed Mohammad Tavangar
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

9.  Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer.

Authors:  Avaniyapuram Kannan Murugan; Chongfei Yang; Mingzhao Xing
Journal:  Oncol Lett       Date:  2013-06-11       Impact factor: 2.967

10.  Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer.

Authors:  Avaniyapuram Kannan Murugan; Eman A Humudh; Ebtesam Qasem; Hindi Al-Hindi; Mai Almohanna; Zeinab Korany Hassan; Ali S Alzahrani
Journal:  Meta Gene       Date:  2015-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.